CStone Pharmaceuticals (2616) AI Stock Analysis

• Market Cap: HK$10.33B
• Dividend Yield: N/A
• Average Volume (3M): 19.75M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: -55.64%
• EPS Growth: -158.67%
• Country: HK
• Employees: 135
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 1,476,015,400
• 10 Day Avg. Volume: 13,736,900
• 30 Day Avg. Volume: 19,747,038
• PEG Ratio: 0.40
• Price to Book (P/B): 7.58
• Price to Sales (P/S): 6.77
• P/FCF Ratio: -8.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$10.30
• Price Target Upside: 92.88% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.14
• Revenue Forecast (FY): HK$401.74M

• Rating: 42 Neutral
• Price Target: HK$5.00 ▼(-6.37% Downside)
• Action: Reiterated Date: 11/05/25
• Date: Action: Reiterated 11/05/25

CStone Pharmaceuticals faces significant financial and operational challenges, with declining revenue and persistent losses being the most impactful factors. The technical indicators suggest bearish momentum, and the negative P/E ratio highlights valuation concerns. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Balance Sheet Strength

A moderate debt load combined with a healthy equity ratio gives CStone structural financial flexibility. This capital base supports ongoing R&D and commercial efforts, reduces near-term refinancing pressure, and provides a buffer while the company works toward operational break-even.

Strategic Partnerships

Established collaborations with global pharma provide durable benefits: access to external expertise, shared development costs, milestone/royalty revenue streams, and faster market entry. These partnerships diversify funding sources and reduce execution risk for late-stage programs.

Oncology-Focused Pipeline

A concentrated oncology and immunotherapy pipeline addresses persistent unmet medical needs, supporting long-term revenue potential. Specialized therapeutic focus creates scientific expertise and potential for durable pricing power and market differentiation if clinical and regulatory milestones succeed.

Negative Factors

Revenue Decline & Losses

Sustained revenue decline and ongoing losses undermine long-term sustainability. Persistent top-line contraction limits reinvestment in R&D and commercialization, increases reliance on external funding, and raises execution risk until revenue growth and profitability can be restored.

Negative Cash Flow

Consistent negative operating and free cash flow forces dependence on financing or partner payments to fund operations. This structural cash burn constrains strategic flexibility, increases dilution or leverage risk, and could delay or impair long-term program advancement.

Negative Margins / Profitability

Persistent negative operating margins indicate structural cost or revenue model issues. Without margin improvement, scaling commercial operations will worsen cash needs and delay achieving sustainable profitability, limiting returns for shareholders over the medium term.

CStone Pharmaceuticals Business Overview & Revenue Model

Company Description

CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.

How the Company Makes Money

CStone Pharmaceuticals generates revenue primarily through the commercialization of its pharmaceutical products, including sales of approved therapies. The company also engages in collaborative partnerships and licensing agreements with other pharmaceutical companies, which provide additional revenue streams through upfront payments, milestone payments, and royalties on sales. Significant partnerships with global pharmaceutical players enhance its research capabilities and market reach, contributing to its overall earnings. Additionally, the company may receive funding from government grants and initiatives aimed at supporting innovative drug development.

CStone Pharmaceuticals Financial Statement Overview

Summary

CStone Pharmaceuticals is experiencing significant financial challenges, with declining revenue and persistent losses. Despite a solid equity position, ongoing negative cash flow and profitability issues pose substantial risks.

Income Statement

CStone Pharmaceuticals has shown a challenging revenue trajectory with declining revenue over the recent years. The company has consistently reported negative EBIT and EBITDA margins, indicating ongoing operational challenges. The net profit margin is also negative, reflecting significant losses, though the scale of losses has decreased over the last year.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio and a healthy equity ratio, suggesting a strong capital base relative to debt. The company has maintained a reasonable balance of assets to liabilities, but the consistent negative net income is a potential risk for long-term sustainability.

Cash Flow

CStone Pharmaceuticals has not demonstrated positive free cash flow in recent years, which is critical for financial health. The operating cash flow is negative, further highlighting liquidity challenges. The absence of growth in free cash flow and reliance on financing activities for cash raises concerns about cash flow sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	177.77M	407.20M	463.84M	481.36M	243.72M	1.04B
Gross Profit	21.73M	240.15M	304.30M	278.38M	136.89M	797.41M
EBITDA	-216.63M	-76.43M	-297.23M	-849.66M	-1.90B	-1.20B
Net Income	-242.00M	-91.21M	-367.23M	-902.68M	-1.92B	-1.22B
Balance Sheet
Total Assets	1.19B	1.39B	1.66B	1.64B	2.27B	3.76B
Cash, Cash Equivalents and Short-Term Investments	690.10M	672.94M	1.05B	1.04B	1.73B	3.39B
Total Debt	391.37M	355.97M	363.45M	286.29M	174.20M	83.86M
Total Liabilities	876.86M	1.03B	1.21B	1.19B	1.06B	808.29M
Stockholders Equity	315.04M	363.87M	456.83M	449.33M	1.21B	2.95B
Cash Flow
Free Cash Flow	-156.05M	-343.18M	-653.89M	-714.29M	-1.63B	-579.52M
Operating Cash Flow	-156.05M	-343.18M	-588.84M	-612.47M	-1.48B	-508.07M
Investing Cash Flow	-149.95M	-247.68M	619.61M	365.12M	-826.55M	1.18B
Financing Cash Flow	22.58M	-12.90M	388.36M	28.47M	92.30M	1.39B

CStone Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.34
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2616, the sentiment is Positive. The current price of 5.34 is below the 20-day moving average (MA) of 6.30, below the 50-day MA of 5.85, and below the 200-day MA of 6.47, indicating a bullish trend. The MACD of 0.35 indicates Negative momentum. The RSI at 63.31 is Neutral, neither overbought nor oversold. The STOCH value of 82.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2616.

CStone Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2256	57 Neutral	HK$8.24B	135.64	6.73%	―	23.37%	―
9966	53 Neutral	HK$8.38B	70.01	13.34%	―	206.58%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2142	51 Neutral	HK$10.61B	5.89	35.80%	―	59.70%	239.97%
2179	44 Neutral	HK$1.92B	-2.54	-129.05%	―	―	-18.99%
2616	42 Neutral	HK$10.33B	-9.27	-71.29%	―	-55.64%	-158.67%

CStone Pharmaceuticals Corporate Events

CStone Pharmaceuticals Sets March Board Meeting and Investor Call to Detail 2025 Results and Oncology Pipeline Progress

CStone Pharmaceuticals has scheduled a board meeting for March 26, 2026 to review and approve its audited annual results for the year ended December 31, 2025, after which it will release the results and issue a voluntary announcement. The company will also host an investor conference call on March 27, 2026 to brief shareholders and potential investors on key business updates, including new Phase I data and Phase II progress for its trispecific antibody CS2009, development progress for its ROR1 antibody-drug conjugate CS5001, global commercialization of its PD-L1 antibody sugemalimab, sales performance of GAVRETO following its inclusion in China’s National Reimbursement Drug List from January 2026, and plans for advancing its preclinical pipeline and upcoming IND applications, signaling continued pipeline execution and commercialization momentum in its oncology portfolio.

The most recent analyst rating on (HK:2616) stock is a Sell with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.

CStone CEO Boosts Stake to 4.87% in Sign of Long-Term Confidence

CStone Pharmaceuticals announced that its CEO, president of research and development, and executive director, Dr. Jianxin Yang, has further increased his personal stake in the company by purchasing 976,000 shares on the open market between November 2025 and January 2026, including 428,500 shares acquired over two days in late January 2026. Since taking over as CEO in August 2022, Dr. Yang has accumulated a total of 12,477,000 shares, bringing his holding to about 4.87% of the company’s issued share capital, which the board interprets as a strong signal of his confidence in CStone’s long-term investment value, operational resilience, and prospects for high-quality growth, and he has indicated he may further increase his shareholding when appropriate.

The most recent analyst rating on (HK:2616) stock is a Sell with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.

CStone Pharmaceuticals Grants New Share Options and RSUs, Seeks Shareholder Nod for Director Awards

CStone Pharmaceuticals’ board has granted 15,715,500 share options to 96 grantees and 8,055,000 restricted share units (RSUs) to 88 grantees under its post-IPO equity incentive schemes, with allocations covering one director and multiple employees including senior management, at no consideration and based on recent market prices. Because the combined options and RSUs awarded to director Dr. Jianxin Yang over a 12‑month period exceed 1% of the company’s issued share capital, these grants are subject to shareholder approval at the upcoming annual general meeting, highlighting both an expanded management incentive program and potential dilution that shareholders and investors are being cautioned to consider.

The most recent analyst rating on (HK:2616) stock is a Sell with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.

CStone Pharmaceuticals Reshapes Board With New Independent Director Appointment

CStone Pharmaceuticals has appointed veteran accounting and assurance professional Catherine Yen as an independent non-executive director, effective 21 January 2026, and named her chairperson of the compensation committee as well as a member of the audit and nomination committees. Yen, a former Ernst & Young China practice partner with more than 35 years of experience and strong credentials in IPOs, M&A, and talent strategy, is expected to strengthen CStone’s corporate governance and oversight as the company continues to navigate capital markets and regulatory expectations. Concurrently, independent non-executive director Anthony Wu has resigned from the board and its key committees due to other commitments, prompting this refresh in the company’s board and committee composition.

The most recent analyst rating on (HK:2616) stock is a Sell with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.

CStone Pharmaceuticals Sets Out Board and Committee Structure

CStone Pharmaceuticals has announced the current composition of its board of directors and detailed the allocation of roles across its five board committees. The company confirmed Dr. Jianxin Yang as executive director and chief executive officer, with Dr. Wei Li serving as non-executive chairman, supported by a mix of non-executive and independent non-executive directors who chair and sit on key committees including audit, compensation, nomination, strategy and investment, underscoring an emphasis on corporate governance and strategic oversight as it advances its oncology-focused business.

The most recent analyst rating on (HK:2616) stock is a Sell with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.

CStone Pharmaceuticals’ GAVRETO® Gains Inclusion in China’s National Reimbursement Drug List

CStone Pharmaceuticals announced the inclusion of GAVRETO® (pralsetinib) in China’s National Reimbursement Drug List (NRDL), effective January 1, 2026. This inclusion marks a significant milestone for CStone, enhancing its market presence in Greater China and potentially increasing accessibility for patients with RET fusion-positive cancers. The drug, developed in collaboration with Blueprint Medicines, is already approved in several regions, including the U.S., Hong Kong, and Taiwan, for treating specific types of cancer, and this development is expected to strengthen CStone’s position in the oncology sector.

The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.

CStone’s Sugemalimab Gains European Approval for Broader NSCLC Treatment

CStone Pharmaceuticals announced that the European Commission has approved sugemalimab as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer (NSCLC) with specific genetic profiles. This approval expands sugemalimab’s indication to cover a broader spectrum of NSCLC, providing a new treatment option for patients in Europe. The achievement highlights CStone’s commitment to enhancing global accessibility of its therapies and addressing unmet medical needs in oncology.

The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.

CStone Pharmaceuticals Unveils CS2015 at ACAAI 2025

CStone Pharmaceuticals has announced the international debut of its bispecific antibody, CS2015, at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI). This marks the first presentation of CS2015 at an international conference, highlighting its potential impact on the treatment of type 2 inflammation. The molecule’s unique design targets OX40L and TSLP, crucial regulators of inflammation, and offers a strong developability profile for scalable manufacturing, indicating significant advancements in therapeutic options for autoimmune and inflammatory diseases.

The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.

CStone Pharmaceuticals Advances CS2009 Clinical Trials with NMPA Approval

CStone Pharmaceuticals announced the approval of their Investigational New Drug application by the China National Medical Products Administration for Phase II clinical trials of CS2009, a tri-specific antibody targeting PD-1, VEGF, and CTLA-4, for advanced solid tumors. This approval is expected to accelerate the clinical development of CS2009, which is currently enrolling patients in Australia and will soon expand to China and the United States, potentially strengthening CStone’s position in the biopharmaceutical industry and offering new therapeutic options for various cancers.

The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.